| [1] |
Siegel R, Ma J, Zou Z, et al.Cancer statistics,2014[J].CA Cancer J Clin,2014,64(1):9-29.
|
| [2] |
陈万青,张思维,曾红梅,等.中国2010 年恶性肿瘤发病与死亡[J].中国肿瘤,2014,23(1):1-10.
|
| [3] |
Cuzick J, Sestak I, Bonanni B, et al.Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data[J].Lancet,2013,381(9880):1827-1834.
|
| [4] |
Goss PE, Ingle JN, Alés-Martínez JE, et al.Exemestane for breast-cancer prevention in postmenopausal women[J].N Engl J Med,2011,364(25):2381-2391.
|
| [5] |
Cuzick J,Sestak I,Forbes JF,et al.Anastrozole for prevention of breast cancer in high-risk postmenopausal women(IBIS-Ⅱ):an international, double-blind, randomised placebo-controlled trial[J].Lancet,2014,383(9922):1041-1048.
|
| [6] |
Moyer VA, U.S.Preventive Services Task Force.Medications to decrease the risk for breast cancer in women:recommendations from the U.S.Preventive Services Task Force recommendation statement [J].Ann Intern Med,2013,159(10):698-708.
|
| [7] |
Visvanathan K, Hurley P, Bantug E, et al.Use of pharmacologic interventions for breast cancer risk reduction:American Society of Clinical Oncology clinical practice guideline[J].J Clin Oncol,2013,31(23):2942-2962.
|
| [8] |
National Comprehensive Cancer Network.Breast cancer risk reduction (version 1.2014).NCCN clinical practice guidelines in oncology[EB/OL].[2015-01-20].http/ /www.nccn.org.
|
| [9] |
Waters EA, McNeel TS, Stevens WM, et al.Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010[J].Breast Cancer Res Treat,2012,134(2):875-880.
|
| [10] |
Freedman AN, Graubard BI, Rao SR, et al.Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention[J].J Natl Cancer Inst,2003,95(7):526-532.
|
| [11] |
Waters EA, Cronin KA, Graubard BI, et al.Prevalence of tamoxifen use for breast cancer chemoprevention among U.S.women[J].Cancer Epidemiol Biomarkers Prev,2010,19(2):443-446.
|
| [12] |
Razzaboni E, Toss A, Cortesi L,et al.Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian Cancer Center (Italy)[J].Breast J, 2013,19(1):10-21.
|
| [13] |
Loehberg CR, Jud SM, Haeberle L, et al.Breast cancer risk assessment in a mammography screening program and participation in the IBIS-Ⅱchemoprevention trial[J].Breast Cancer Res Treat,2010,121(1):101-110.
|
| [14] |
Ropka ME, Keim J, Philbrick JT, et al.Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis [J].J Clin Oncol,2010,28(18):3090-3095.
|
| [15] |
Cameron DA.Breast cancer chemoprevention: little progress in practice? [J].Lancet,2014,383(9922):1018-1020.
|
| [16] |
Costantino JP, Gail MH, Pee D, et al.Validation studies for models projecting the risk of invasive and total breast cancer incidence[J].J Natl Cancer Inst,1999,91(18):1541-1548.
|
| [17] |
Guerra CE, Sherman M, Armstrong K.Diffusion of breast cancer risk assessment in primary care[J].J Am Board Fam Med,2009,22(3):272-279.
|
| [18] |
Sabatino SA, McCarthy EP, Phillips RS, et al.Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers[J].Cancer Detect Prev,2007,31(5):375-383.
|
| [19] |
Kaplan CP, Haas JS, Pérez-Stable EJ, et al.Factors affecting breast cancer risk reduction practices among California physicians[J].Prev Med,2005,41(1):7-15.
|
| [20] |
Ravdin PM.The lack, need, and opportunities for decisionmaking and informational tools to educate primary-care physicians and women about breast cancer chemoprevention[J].Cancer Prev Res (Phila),2010,3(6):686-688.
|
| [21] |
Reimers L,Crew KD.Tamoxifen vs raloxifene vs exemestane for chemoprevention[J].Curr Breast Cancer Rep, 2012,4(3):207-215.
|
| [22] |
Owens WL, Gallagher TJ, Kincheloe MJ, et al.Implementation in a large health system of a program to identify women at high risk for breast cancer[J].J Oncol Pract,2011,7(2):85-88.
|
| [23] |
Fagerlin A,Dillard AJ,Smith DM,et al.Women's interest in taking tamoxifen and raloxifene for breast cancer prevention:response to a tailored decision aid[J].Breast Cancer Res Treat,2011,127(3):681-688.
|
| [24] |
Bober SL, Hoke LA, Duda RB, et al.Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors[J].J Clin Oncol, 2004,22 (24):4951-4957.
|
| [25] |
Rondanina G, Puntoni M, Severi G, et al.Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users[J].J Clin Oncol,2008,26(9):1537-1543.
|
| [26] |
Tchou J, Hou N, Rademaker A, et al.Acceptance of tamoxifen chemoprevention by physicians and women at risk[J].Cancer,2004,100(9):1800-1806.
|
| [27] |
郑莹,吴春晓,张璐敏.乳腺癌在中国的流行状况和疾病特征[J].中国癌症杂志,2013,23(8):561-569.
|
| [28] |
Li J, Zhang BN, Fan JH, et al.A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China[J].BMC Cancer, 2011,11:364.
|
| [29] |
中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2013 版)[J].中国癌症杂志, 2013,23(8):637-684.
|
| [30] |
李建梅,王维,李少英.Gail 乳腺癌风险评估模型应用初探[J].中国当代医药,2009,16(14):40-41.
|
| [31] |
李建梅, 王维, 李少英.Gail 乳腺癌评估模型在乳腺癌社区预防的应用[J].中国妇幼保健,2013,28(3):414-417.
|